1278 related articles for article (PubMed ID: 19470732)
41. Clinical proteomics in breast cancer: a review.
Gast MC; Schellens JH; Beijnen JH
Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
43. Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS.
Xue A; Gandy RC; Chung L; Baxter RC; Smith RC
Pancreatology; 2012; 12(2):124-9. PubMed ID: 22487522
[TBL] [Abstract][Full Text] [Related]
44. [Proteinchip-flight mass spectrometry for screening differentially expressed proteins in the serum of cervical cancer patients].
Cai SN; Liu GB; Guo XH; Chen JG; Zhang J; Wu YL; Liang WJ; Luo RC
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jan; 29(1):32-5. PubMed ID: 19218106
[TBL] [Abstract][Full Text] [Related]
45. Influence of blood sampling on protein profiling and pattern analysis using matrix-assisted laser desorption/ionisation mass spectrometry.
Pelzer AE; Feuerstein I; Fuchsberger C; Ongarello S; Bektic J; Schwentner C; Klocker H; Bartsch G; Bonn GK
BJU Int; 2007 Mar; 99(3):658-62. PubMed ID: 17407520
[TBL] [Abstract][Full Text] [Related]
46. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
47. Optimal preparation methods for automated matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling of low molecular weight proteins and peptides.
Penno MA; Ernst M; Hoffmann P
Rapid Commun Mass Spectrom; 2009 Sep; 23(17):2656-62. PubMed ID: 19630030
[TBL] [Abstract][Full Text] [Related]
48. Construction of a multiple myeloma diagnostic model by magnetic bead-based MALDI-TOF mass spectrometry of serum and pattern recognition software.
Wang QT; Li YZ; Liang YF; Hu CJ; Zhai YH; Zhao GF; Zhang J; Li N; Ni AP; Chen WM; Xu Y
Anat Rec (Hoboken); 2009 Apr; 292(4):604-10. PubMed ID: 19301277
[TBL] [Abstract][Full Text] [Related]
49. Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer.
Ueda K; Katagiri T; Shimada T; Irie S; Sato TA; Nakamura Y; Daigo Y
J Proteome Res; 2007 Sep; 6(9):3475-83. PubMed ID: 17705522
[TBL] [Abstract][Full Text] [Related]
50. The potential biomarkers for thromboembolism detected by SELDI-TOF-MS.
Hong M; Zhang X; Hu Y; Wang H; He W; Mei H; Yu J; Guo T; Song S
Thromb Res; 2009; 123(3):556-64. PubMed ID: 18620739
[TBL] [Abstract][Full Text] [Related]
51. Establishment of serum protein pattern for screening colorectal cancer using SELDI-TOF-MS.
Zheng GX; Wang CX; Qu X; Deng XM; Deng BP; Zhang J
Exp Oncol; 2006 Dec; 28(4):282-7. PubMed ID: 17285111
[TBL] [Abstract][Full Text] [Related]
52. [Identification of serum biomarkers for ovarian cancer using protein chips and time of flight mass spectrometry technology].
Wang Q; Li L; Li DR; Zhang W; Wei X; Zhang JQ; Tang Y
Zhonghua Fu Chan Ke Za Zhi; 2006 Aug; 41(8):544-8. PubMed ID: 17083841
[TBL] [Abstract][Full Text] [Related]
53. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.
Ye B; Skates S; Mok SC; Horick NK; Rosenberg HF; Vitonis A; Edwards D; Sluss P; Han WK; Berkowitz RS; Cramer DW
Clin Cancer Res; 2006 Jan; 12(2):432-41. PubMed ID: 16428483
[TBL] [Abstract][Full Text] [Related]
54. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
[TBL] [Abstract][Full Text] [Related]
55. Data analysis of assorted serum peptidome profiles.
Villanueva J; Philip J; DeNoyer L; Tempst P
Nat Protoc; 2007; 2(3):588-602. PubMed ID: 17406620
[TBL] [Abstract][Full Text] [Related]
56. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
[TBL] [Abstract][Full Text] [Related]
57. Urinary CD14 as a potential biomarker for benign prostatic hyperplasia - discovery by combining MALDI-TOF-based biostatistics and ESI-MS/MS-based stable-isotope labeling.
Cheng HL; Huang HJ; Ou BY; Chow NH; Chen YW; Tzai TS; Wu CJ; Chen SH
Proteomics Clin Appl; 2011 Apr; 5(3-4):121-32. PubMed ID: 21322116
[TBL] [Abstract][Full Text] [Related]
58. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.
Jackson D; Craven RA; Hutson RC; Graze I; Lueth P; Tonge RP; Hartley JL; Nickson JA; Rayner SJ; Johnston C; Dieplinger B; Hubalek M; Wilkinson N; Perren TJ; Kehoe S; Hall GD; Daxenbichler G; Dieplinger H; Selby PJ; Banks RE
Clin Cancer Res; 2007 Dec; 13(24):7370-9. PubMed ID: 18094419
[TBL] [Abstract][Full Text] [Related]
59. Acid hydrolysis followed by matrix-assisted laser desorption/ionization mass spectrometry for the rapid diagnosis of serum protein biomarkers in patients with major depression.
Lo LH; Huang TL; Shiea J
Rapid Commun Mass Spectrom; 2009 Mar; 23(5):589-98. PubMed ID: 19165777
[TBL] [Abstract][Full Text] [Related]
60. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
Geng X; Wang F; Li YG; Zhu GP; Zhang WM
J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
